Santhera Pharmaceuticals Holding AG (0QN1.L)
0QN1.L Stock Price Chart
Explore Santhera Pharmaceuticals Holding AG interactive price chart. Choose custom timeframes to analyze 0QN1.L price movements and trends.
0QN1.L Company Profile
Discover essential business fundamentals and corporate details for Santhera Pharmaceuticals Holding AG (0QN1.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
6 Mar 2014
Employees
78.00
Website
https://www.santhera.comCEO
Dario Eklund
Description
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
0QN1.L Financial Timeline
Browse a chronological timeline of Santhera Pharmaceuticals Holding AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 10 Sept 2025
Revenue estimate is CHF 9.00M.
Earnings released on 29 Apr 2025
EPS came in at -CHF 2.34, while revenue for the quarter reached CHF 25.00M, beating expectations by +177.81%.
Earnings released on 12 Sept 2024
EPS came in at -CHF 1.35, while revenue for the quarter reached CHF 14.11M, beating expectations by +152.04%.
Earnings released on 25 Apr 2024
EPS came in at CHF 7.00, while revenue for the quarter reached CHF 99.44M.
Stock split effective on 3 Jul 2023
Shares were split 1:10, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2023
EPS came in at -CHF 2.09, while revenue for the quarter reached CHF 3.94M.
Earnings released on 31 Dec 2022
EPS came in at -CHF 6.43, while revenue for the quarter reached CHF 1.22M.
Earnings released on 30 Jun 2022
EPS came in at -CHF 5.24, while revenue for the quarter reached CHF 6.25M.
Earnings released on 31 Dec 2021
EPS came in at -CHF 7.06 surpassing the estimated -CHF 7.60 by +7.11%, while revenue for the quarter reached -CHF 6.09M, missing expectations by -343.48%.
Earnings released on 30 Jun 2021
EPS came in at -CHF 9.22, while revenue for the quarter reached CHF 4.49M.
Earnings released on 31 Dec 2020
EPS came in at -CHF 23.01, while revenue for the quarter reached CHF 7.23M.
0QN1.L Stock Performance
Access detailed 0QN1.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.